论文部分内容阅读
利用逆转录 聚合酶链反应 (RT PCR)技术分别检测 4 9例初治病人及 12例化疗、8例BMT后病人不同时期骨髓细胞AML1/ETOmRNA的表达。结果显示 :①AML1/ETOmRNA可表达于AML M2 ,AML M4及MDS RAEB T中 ;② 9例病人化疗后、5例Allo BMT及 1例Auto PBSCT后RT PCR结果分别转为阴性并处于持续完全缓解状态 ,2例化疗病人由阴性转为阳性而后复发 ,1例化疗病人持续弱阳性后转阳性并复发。 2例Allo BMT病人移植后持续阳性并分别死于复发及GVHD。研究结果提示 ,化疗及骨髓移植可以使RT PCRAML1/ETOmRNA转为阴性 ;由阴性转阳性或持续阳性可能预示复发 ,因而定期监测是必要的
Reverse transcription polymerase chain reaction (RT PCR) was used to detect the expression of AML1/ETO mRNA in bone marrow cells of 49 untreated patients and 12 patients treated with chemotherapy and 8 after BMT. The results showed that: 1 AML1/ETO mRNA can be expressed in AML M2, AML M4 and MDS RAEB T; 29 cases of patients after chemotherapy, 5 cases of Allo BMT and 1 case of Auto PBSCT RT PCR results were negative and in a sustained state of complete remission , 2 cases of chemotherapy patients from the negative to positive and then relapse, 1 case of chemotherapy patients continued to return positive and relapse after weak positive. Two patients with Allo BMT remained positive after transplantation and died of relapse and GVHD. The results suggest that chemotherapy and bone marrow transplantation can make RT PCRAML1/ETO mRNA negative; negative to positive or persistent positive may predict recurrence, so regular monitoring is necessary